Welcome to our dedicated page for Petmed Express SEC filings (Ticker: PETS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PetMed Express Inc鈥檚 business lives at the intersection of e-commerce and pet healthcare, so its SEC disclosures hold clues that go far beyond routine numbers. Curious about how prescription refills stack up against over-the-counter sales or how marketing spend drives new pet-parent acquisitions? This is where you鈥檒l find out.
Stock Titan鈥檚 AI engine turns each dense document into plain-English takeaways. Need the PetMed Express quarterly earnings report 10-Q filing distilled to the metrics that matter鈥攇ross margin shifts, customer reorder rates, seasonal flea & tick demand? Our platform surfaces them instantly. Wondering whether executives are buying shares before high-growth quarters? PetMed Express Form 4 insider transactions real-time alerts put that data at your fingertips.
Here鈥檚 what you can explore today:
- 10-K insights: inventory turnover, prescription vs OTC mix, and customer acquisition cost鈥�PetMed Express annual report 10-K simplified
- AG真人官方-time PetMed Express insider trading Form 4 transactions plus historical trend charts
- PetMed Express proxy statement executive compensation that connects pay to reorder growth
- PetMed Express 8-K material events explained鈥攕upplier changes, data-security updates, partnership launches
Every filing type鈥�10-Q, 10-K, 8-K, DEF 14A, and S-8鈥攁rrives seconds after EDGAR posts. AI-powered summaries, keyword search, and side-by-side comparisons make understanding PetMed Express SEC documents with AI straightforward. Use our PetMed Express earnings report filing analysis to track margin trends, or monitor PetMed Express executive stock transactions Form 4 before making allocation decisions. Complex pet-pharma disclosures, simplified and updated in real time鈥攕o you can focus on actionable insights, not page counts.
PetMed Express reported that on August 11, 2025 its Chief Executive Officer and President, Sandra Campos, and its Chief Financial Officer and Treasurer, Robyn D鈥橢lia, resigned effective immediately. Under separation agreements the Company will continue each officer鈥檚 annual base salary for 13 months ($550,000 for Ms. Campos; $425,000 for Ms. D鈥橢lia), reimburse COBRA premiums for 18 months, and accelerate pro鈥憆ata vesting of certain restricted stock units while other equity awards will be forfeited. The Board reduced its size from six to five and appointed Leslie C.G. Campbell as Interim CEO and President and Doug Krulik as Interim Principal Financial Officer (while he continues as Chief Accounting Officer). The filing discloses an ongoing Audit Committee investigation into autoship revenue recognition, a $50 coupon promotion, and the company鈥檚 control environment; a press release was furnished as Exhibit 99.1.
PetMed Express, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 because the company's Audit Committee investigation described in a Current Report filed July 1, 2025 remains incomplete.
The company says completion of that investigation is required to finish and file its Annual Report for the fiscal year ended March 31, 2025, which must be filed before the 10-Q. PetMed indicates a significant change in results is anticipated but cannot reasonably estimate amounts at this time. Contact: Robert Lawsky, General Counsel.
PetMed Express (PETS) Form 4 filing: On 18 Jul 2025, 10% owner Silvercape Investments Ltd purchased 17,565 common shares at $3.23 each (鈮�$56.7 k). The move raises its directly held stake to 2,360,496 shares. No sales or derivative transactions were disclosed. While the add-on represents only ~0.7% of the owner鈥檚 position, continued buying from a >10% holder can signal confidence without materially altering the share count or control position.
PetMed Express Inc. (PETS) Form 4 filing reports that 10% owner Silvercape Investments Ltd purchased 2,817 common shares on 07 July 02 2025 at $3.22 per share, for an outlay of roughly $9.1 thousand. Following the transaction, Silvercape directly holds 2,311,230 shares of PETS. The purchase increases the investor鈥檚 stake by about 0.12%, indicating incremental but limited additional commitment to the company.
FAQ
What is the current stock price of Petmed Express (PETS)?
What is the market cap of Petmed Express (PETS)?
